Abstract
Two malaria transmission-blocking vaccine (TBV) candidates, R0.6C and ProC6C, have completed preclinical development including the selection of adjuvants, Alhydrogel® with or without the saponin based adjuvant Matrix-M™. Here, we report on the final drug product (formulation) design of R0.6C and ProC6C and evaluate their safety and biochemical stability in preparation for preclinical and clinical pharmacy handling. The point-of-injection stability studies demonstrated that both the R0.6C and ProC6C antigens are stable on Alhydrogel in the presence or absence of Matrix-M for up to 24 h at room temperature. As this is the first study to combine Alhydrogel and Matrix-M for clinical use, we also evaluated their potential interactions. Matrix-M adsorbs to Alhydrogel, while not displacing the > 95 % adsorbed protein. The R0.6C and ProC6C formulations were found to be safe and well tolerated in repeated dose toxicity studies in rabbits generating high levels of functional antibodies that blocked infection of mosquitoes. Further, the R0.6C and ProC6C drug products were found to be stable for minimally 24 months when stored at 2–8 °C, with studies ongoing through 36 months. Together, this data demonstrates the safety and suitability of the L. lactis expression system as well as supports the clinical testing of the R0.6C and ProC6C malaria vaccine candidates in First-In-Human clinical trials.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Vaccine |
Vol/bind | 42 |
Udgave nummer | 8 |
Sider (fra-til) | 1980-1992 |
ISSN | 0264-410X |
DOI | |
Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:This project is part of and funded by the EDCTP2 Programme supported by the European Union and Developing Countries Clinical Trials Partnership (Grant number RIA2018SV-2311 ). The views and opinions of authors expressed herein do not necessarily state or reflect those of EDCTP.
Publisher Copyright:
© 2024 The Author(s)